Bio-Techne Corp (TECH)
Stock Price:
$263.73 USD
-4.15 (-1.55%)
Updated Aug 6, 2020 12:01 PM EDT - Market open
Key Info
| Market Cap |
10.08B |
| Revenue (ttm) |
754.52M |
| Net Income (ttm) |
186.91M |
| Shares Out |
38.22M |
| EPS (ttm) |
4.76 |
| PE Ratio |
55.40 |
| Forward PE |
52.36 |
| Dividend |
$1.28 |
| Dividend Yield |
0.49% |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$263.73 |
| Previous Close |
$267.87 |
| Change ($) |
-4.15 |
| Change (%) |
-1.55% |
| Day's Open |
270.47 |
| Day's Range |
262.34 - 271.22 |
| Day's Volume |
32,595 |
| 52-Week Range |
155.17 - 286.68 |
More Stats
| Market Cap |
10.08B |
| Enterprise Value |
10.32B |
| Earnings Date (est) |
Nov 3, 2020 |
| Ex-Dividend Date |
May 8, 2020 |
| Shares Outstanding |
38.22M |
| Float |
38.01M |
| EPS (basic) |
4.89 |
| EPS (diluted) |
4.76 |
| FCF / Share |
4.45 |
| Dividend |
$1.28 |
| Dividend Yield |
0.49% |
| Earnings Yield |
1.80% |
| FCF Yield |
1.69% |
| Payout Ratio |
26.20% |
| Shares Short |
589,993 |
| Short Ratio |
2.95 |
| Short % of Float |
1.67% |
| Beta |
1.14 |
| PE Ratio |
55.40 |
| Forward PE |
52.36 |
| P/FCF Ratio |
59.19 |
| PS Ratio |
13.36 |
| PB Ratio |
8.15 |
| Revenue |
754.52M |
| Operating Income |
161.37M |
| Net Income |
186.91M |
| Free Cash Flow |
170.31M |
| Net Cash |
-237.80M |
| Net Cash / Share |
-6.22 |
| Gross Margin |
63.25% |
| Operating Margin |
21.39% |
| Profit Margin |
24.80% |
| FCF Margin |
22.57% |
| ROA |
5.22% |
| ROE |
15.34% |
| ROIC |
27.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
4 |
| Overweight |
1 |
| Hold |
4 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$255.88*
(-2.97% downside)
Low
211
Current: $263.73
High
320
Target: 255.88
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 714 | 643 | 563 | 499 | 452 | 358 | 311 | 315 | 290 | 269 |
| Revenue Growth | 11.04% | 14.21% | 12.82% | 10.34% | 26.41% | 15.19% | -1.27% | 8.48% | 7.77% | - |
| Gross Profit | 473 | 432 | 375 | 337 | 307 | 251 | 231 | 236 | 225 | 214 |
| Operating Income | 147 | 136 | 121 | 151 | 147 | 160 | 158 | 166 | 163 | 156 |
| Net Income | 96.07 | 126 | 76.09 | 104 | 108 | 111 | 113 | 112 | 112 | 110 |
| Shares Outstanding | 37.78 | 37.48 | 37.31 | 37.19 | 37.10 | 36.89 | 36.84 | 36.94 | 37.10 | 37.26 |
| Earnings Per Share | 2.47 | 3.31 | 2.03 | 2.80 | 2.89 | 3.00 | 3.05 | 3.04 | 3.02 | 2.94 |
| EPS Growth | -25.38% | 63.05% | -27.5% | -3.11% | -3.67% | -1.64% | 0.33% | 0.66% | 2.72% | - |
| Dividend Per Share | 1.28 | 1.28 | 1.28 | 1.28 | 1.27 | 1.23 | 1.18 | 1.11 | 1.07 | 1.03 |
| Dividend Growth | 0% | 0% | 0% | 0.79% | 3.25% | 4.24% | 6.31% | 3.74% | 3.88% | - |
| Operating Cash Flow | 182 | 170 | 144 | 144 | 139 | 137 | 124 | 127 | 127 | 111 |
| Capital Expenditures | -25.41 | -20.93 | -15.18 | -16.90 | -19.91 | -13.82 | -22.45 | -6.02 | -3.63 | -4.64 |
| Free Cash Flow | 156 | 149 | 129 | 127 | 119 | 123 | 101 | 121 | 124 | 107 |
| Cash & Equivalents | 166 | 182 | 158 | 95.84 | 111 | 363 | 333 | 269 | 141 | 139 |
| Total Debt | 505 | 339 | 344 | 95.26 | 77.02 | 12.95 | - | - | - | - |
| Net Cash / Debt | -339 | -157 | -186 | 0.58 | 33.90 | 350 | 333 | 269 | 141 | 139 |
| Assets | 1,884 | 1,593 | 1,558 | 1,130 | 1,063 | 862 | 778 | 719 | 618 | 519 |
| Liabilities | 719 | 514 | 609 | 250 | 216 | 67.23 | 40.56 | 44.88 | 31.55 | 17.02 |
| Book Value | 1,166 | 1,079 | 950 | 879 | 847 | 795 | 738 | 674 | 586 | 502 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Bio-Techne Corp |
| Country |
United States |
| Employees |
2,200 |
| CEO |
Charles R. Kummeth |
Stock Information
| Ticker Symbol |
TECH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TECH |
| IPO Date |
February 9, 1989 |
Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. Bio-Techne Corporation has partnership with Kantaro Biosciences to develop and scale production of COVID-19 serology test. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.